secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001558370-23-015014
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio reports 4 of 4 indolent lymphoma patients respond to MB-106 CAR T; dose escalation approved
--------------------------------------------------------------------------------

- Clinical responses in 4 of 4 indolent lymphoma patients at starting dose 3.3x10^6 CAR T cells/kg; 2 follicular lymphoma patients achieved CR.
- Safety Review Committee unanimously approved dose escalation to 1.0x10^7 CAR T cells/kg; only Grade 1 CRS reported.
- Fred Hutch trial (n=20 FL) shows 95% ORR, 80% CR; first patient sustained CR >3 years.
- Waldenstrom macroglobulinemia cohort (n=6): 2 CR, one ongoing >22 months; no CRS/ICANS >Grade 2.
- Pivotal Phase 2 for WM to start mid-2024, top-line data mid-2026; end-of-Phase 1 FDA meeting expected end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023015014/0001558370-23-015014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023015014/tmb-20230816x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer